Delivering Transformational Benefit with TCR-Based Therapies for PRAME Positive Cancers
10:30 am - Tuesday 19th May 2026
- Demonstrating first-generation autologous TCR therapy Anzu-Cel achieving 50-60% durable responses in melanoma
- Advancing second-generation efficacy enhanced PRAME TCRs into ovarian and endometrial cancers and the prospect of tissue agnostic expansion
- Bispecific TCR approaches to maximize clinical impact while addressing development and scalability challenges
